AA
NKGN

Ancora Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Ancora Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$10K – 2007
2022
Q3 		$10K Hold
1,000
– – ﹤0.01% 1499
2022
Q2 		$10K Hold
1,000
– – ﹤0.01% 1605
2022
Q1 		$10K Buy
+1,000
New +$9.69K ﹤0.01% 1741

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ancora Advisors's NKGN Position: Q4 2022 in Review

Ancora Advisors sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2022, closing a stake of 1,000 shares — an estimated $10K sold.

Ancora Advisors first reported a position in NKGN in Q1 2022 and held it in 3 quarters. The position peaked at $10K in Q3 2022. 59 funds tracked by Wall St. Rank hold NKGN as of Q4 2022.

  • Ancora Advisors reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ancora Advisors sold 1,000 NKGen Biotech, Inc. Common Stock shares in Q4 2022, an estimated $10K.
  • Ancora Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Ancora Advisors's NKGen Biotech, Inc. Common Stock position peaked at $10K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2022.

Based on Ancora Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.